Cargando…

Poster: CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience

Detalles Bibliográficos
Autores principales:	Mavilia, Fabrizio, Pratesi, Federico, Baratè, Claudia, Benedetti, Edoardo, Guerri, Valentina, Sammuri, Paola, Migliorini, Paola, Galimberti, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Leukemia & Related Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489246/ http://dx.doi.org/10.1016/S2152-2650(22)00850-3

Ejemplares similares

CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022)

Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience
por: Baratè, Claudia, et al.
Publicado: (2022)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Poster: CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
por: Trajkova, Sanja, et al.
Publicado: (2022)

Poster: CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

Poster: CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

Poster: CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients – A Prospective Study
por: Galvis, Marisol Miranda, et al.
Publicado: (2022)

Poster: ALL-206 Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country
por: Hammad, Mahmoud, et al.
Publicado: (2022)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
por: Oscier, David, et al.
Publicado: (2016)

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

CLL-393 Outcomes of COVID-19 Infections in Patients With Hematological Malignancies in Republic of North Macedonia
por: Cvetanoski, Milche, et al.
Publicado: (2022)

CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
por: Trajkova, Sanja, et al.
Publicado: (2022)

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma
por: Lichtman, Marshall A.
Publicado: (2010)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Frequency of 11q23/MLL gene rearrangement in Egyptian childhood acute myeloblastic leukemia: Biologic and clinical significance
por: Hagag, Adel Abdelhaleim, et al.
Publicado: (2014)

A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy
por: Tuscano, Carmelo, et al.
Publicado: (2017)

C–C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation
por: Kubeczko, Marcin, et al.
Publicado: (2016)

The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
por: Else, Monica, et al.
Publicado: (2015)

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease
por: Benedetti, Edoardo, et al.
Publicado: (2023)

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)
por: Molica, Stefano, et al.
Publicado: (2021)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
por: Terpos, Evangelos, et al.
Publicado: (2021)

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL
por: Sun, Clare, et al.
Publicado: (2021)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
por: Benedetti, Edoardo, et al.
Publicado: (2022)

Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
por: Mato, Anthony, et al.
Publicado: (2023)

A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients
por: Chbat, Maureen, et al.
Publicado: (2021)

BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers
por: Pratesi, Federico, et al.
Publicado: (2021)

Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies
por: Caruso, Teresita, et al.
Publicado: (2023)

Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies
por: Caruso, Teresita, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_12t5i4plohpephbls3o0bcljga